1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/06/2024 | MET | Buy Now | MetLife | $72.70 | 14.17% | Wells Fargo | Elyse Greenspan | $85 → $83 | Maintains | Overweight | Get Alert |
02/05/2024 | MET | Buy Now | MetLife | $72.70 | 12.79% | UBS | Brian Meredith | $87 → $82 | Maintains | Buy | Get Alert |
01/10/2024 | MET | Buy Now | MetLife | $72.70 | 19.67% | UBS | Brian Meredith | $84 → $87 | Maintains | Buy | Get Alert |
01/09/2024 | MET | Buy Now | MetLife | $72.70 | 10.04% | Goldman Sachs | Alex Scott | $70 → $80 | Maintains | Buy | Get Alert |
01/08/2024 | MET | Buy Now | MetLife | $72.70 | 10.04% | Goldman Sachs | Alex Scott | → $80 | Upgrade | Neutral → Buy | Get Alert |
12/07/2023 | MET | Buy Now | MetLife | $72.70 | 5.91% | Keefe, Bruyette & Woods | Ryan Krueger | $79 → $77 | Maintains | Outperform | Get Alert |
11/17/2023 | MET | Buy Now | MetLife | $72.70 | -2.34% | Barclays | Tracy Benguigui | → $71 | Reinstates | → Overweight | Get Alert |
11/02/2023 | MET | Buy Now | MetLife | $72.70 | 10.04% | Morgan Stanley | Nigel Dally | $79 → $80 | Maintains | Overweight | Get Alert |
10/06/2023 | MET | Buy Now | MetLife | $72.70 | 12.79% | JP Morgan | Jimmy Bhullar | $85 → $82 | Maintains | Overweight | Get Alert |
09/14/2023 | MET | Buy Now | MetLife | $72.70 | -0.96% | Jefferies | Suneet Kamath | $58 → $72 | Upgrade | Hold → Buy | Get Alert |
08/18/2023 | MET | Buy Now | MetLife | $72.70 | 8.67% | Morgan Stanley | Nigel Dally | $78 → $79 | Maintains | Overweight | Get Alert |
08/15/2023 | MET | Buy Now | MetLife | $72.70 | 14.17% | Wells Fargo | Elyse Greenspan | $82 → $83 | Maintains | Overweight | Get Alert |
08/14/2023 | MET | Buy Now | MetLife | $72.70 | 5.91% | Argus Research | Kevin Heal | $70 → $77 | Maintains | Buy | Get Alert |
08/09/2023 | MET | Buy Now | MetLife | $72.70 | 11.42% | Citigroup | Michael Ward | $76 → $81 | Maintains | Buy | Get Alert |
08/04/2023 | MET | Buy Now | MetLife | $72.70 | 1.79% | RBC Capital | Mark Dwelle | $70 → $74 | Maintains | Outperform | Get Alert |
08/03/2023 | MET | Buy Now | MetLife | $72.70 | 7.29% | Morgan Stanley | Nigel Dally | $78 → $78 | Reiterates | Overweight → Overweight | Get Alert |
07/17/2023 | MET | Buy Now | MetLife | $72.70 | 12.79% | Wells Fargo | Elyse Greenspan | $75 → $82 | Maintains | Overweight | Get Alert |
06/15/2023 | MET | Buy Now | MetLife | $72.70 | 4.54% | Citigroup | Michael Ward | $85 → $76 | Maintains | Buy | Get Alert |
06/09/2023 | MET | Buy Now | MetLife | $72.70 | 10.04% | Keefe, Bruyette & Woods | Ryan Krueger | $86 → $80 | Reiterates | → Outperform | Get Alert |
The latest price target for MetLife (NYSE: MET) was reported by Wells Fargo on February 6, 2024. The analyst firm set a price target for $83.00 expecting MET to rise to within 12 months (a possible 14.40% upside). 29 analyst firms have reported ratings in the last year.
The latest analyst rating for MetLife (NYSE: MET) was provided by Wells Fargo, and MetLife maintained their overweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MetLife, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MetLife was filed on February 6, 2024 so you should expect the next rating to be made available sometime around February 6, 2025.
While ratings are subjective and will change, the latest MetLife (MET) rating was a maintained with a price target of $85.00 to $83.00. The current price MetLife (MET) is trading at is $72.55, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.